Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumor: early-phase trial registry
133 of 190 indexed Advanced Solid Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #56 of 28,707 conditions by registered trial count.
190 US clinical trials · 133 currently recruiting · #56 of 28,707 conditions by registered trial count
Advanced Solid Tumor: 190 US clinical trials tracked, 133 recruiting.
Advanced Solid Tumor is the subject of 190 registered US clinical trials on ClinicalTrials.gov, 133 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 186 in Phase 1-2 (earlier-stage). The most active sponsor is Daiichi Sankyo, running 7 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumor
OPEN 133 | RECR 70% | LATE 0 | EARLY 186 | RANK #56 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IV Breast Cancer AJCC v8 (70% recruiting · 60 trials)
Advanced Solid Tumor lists 133 open slots (70% of 190 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumor is recruiting above its size-band peers.
133 of 190 indexed trials (70%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Solid Tumor trials is spread across many organizations.
Daiichi Sankyo accounts for 7 of 190 trials (3.7%). 135 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Solid Tumor enrolment sits around 141 participants.
Median target enrolment is 141 among the 190 trials that report a genuine target (sentinel values excluded). 73 of those (38.4%) plan for fewer than 100 participants.
-
Advanced Solid Tumor research is mostly interventional.
188 interventional and 2 observational studies make up this index (98.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
190 total, page 4 of 4
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT04649385
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
Werewolf Therapeutics
NCT05479812
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals
NCT04892017
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
EMD Serono Research & Development Institute
NCT06421935
Study Of ATRN-119 In Patients With Advanced Solid Tumors
Aprea Therapeutics
NCT04905914
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Kahr Medical
NCT04440735
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Replimune
NCT04735978
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT06422520
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
OBI Pharma
NCT06480240
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics
NCT05864144
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
Turning Point Therapeutics
NCT03993873
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT05765851
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
Mural Oncology
NCT04592653
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05948826
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
TORL Biotherapeutics
NCT05159440
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Nuvectis Pharma
NCT05226507
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Treadwell Therapeutics
NCT05251714
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
Sonnet BioTherapeutics
NCT05352750
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Zhuhai Yufan Biotechnologies Co.
NCT05159700
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
National Cancer Institute (NCI)
NCT04802174
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
NCT06685068
Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
Virginia Commonwealth University
NCT04502602
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
TransCode Therapeutics
NCT06260774
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT06237881
Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors
Danae Hamouda, MD
NCT03889795
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
NCT04375228
A Study of NB003 in Patients With Advanced Malignancies
Ningbo Newbay Technology Development Co.
NCT04936178
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
NCT04215978
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
NCT04247126
XTX202 in Patients With Advanced Solid Tumors
Xilio Development
NCT05052268
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Prelude Therapeutics
NCT04089449
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT04200963
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04349267
Oral Administration of STC-15 in Subjects With Advanced Malignancies
STORM Therapeutics
NCT05584111
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Jacobio Pharmaceuticals Co.
NCT05002270
Study of AGEN1571 in Participants With Advanced Solid Tumors
Agenus
NCT05377528
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
EMD Serono Research & Development Institute
NCT02644278
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Jason J. Luke, MD
NCT04056910
Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
ImmunityBio
NCT01673438
A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Elpiscience Biopharma
NCT05075564
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 180 |
| Phase 2 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumor page
190 registered trials, 133 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 133 Advanced Solid Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Daiichi Sankyo sponsors the most Advanced Solid Tumor trials on record, review their full trial history before evaluating a specific study. See Daiichi Sankyo's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumor condition card totals 190 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.